NL-OMON30826
Completed
Not Applicable
Minimal residual disease (MRD) monitoring in neuroblastoma to improve MRD based risk stratification - MRD monitoring in children with neuroblastoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- neuroblastoma
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 60
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- children with high or medium risk neuroblastoma
- •\- treated according to dutch\-german protocol
Exclusion Criteria
- •\- children with low risk neuroblastoma
- •\- children with ganglioneuroma
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Survey on Minimal Residual Disease (MRD) Measurement in Multiple MyelomaMultiple MyelomaJPRN-UMIN000052475Sanofi K.K.158
Withdrawn
Not Applicable
' Biomarkers for minimal residual disease in neuro-oncology ': MIRDINO studyNL-OMON46208Academisch Medisch Centrum400
Completed
Not Applicable
Non-invasive MRD Assessment in Multiple MyelomaMyelomaNCT05625971Rajshekhar Chakraborty, MD36
Active, not recruiting
Not Applicable
Eradication of Minimal Residual Disease (MRD) in patients with Chronic Lymphocytic Leukaemia (CLL) with Alemtuzumab: A Phase II Study - UKCLL07Chronica Lymphocytic Leukaemia (CLL)EUCTR2006-000053-22-GBeeds Teaching Hospitals NHS Trust54
Completed
Not Applicable
Prospective evaluation of minimal residual disease in acute myeloid leukemia using TIM-3 as a leukemia markeracute myeloid leukemiaJPRN-UMIN000030977Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine50